Earnings Ahead

RGNX - REGENXBIO Inc.

19.69 1.27 6.9

  1. Home
  2. Healthcare
  3. RGNX
REGENXBIO Inc.

REGENXBIO Inc.

About

Profile

Headquarters

Rockville, Maryland, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

RGNX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Regenxbio GAAP EPS of -$1.43 misses by $0.26, revenue of $22.21M misses by $11.8M
  • Regenxbio Q4 2023 Earnings Preview
  • Regenxbio spikes after trial win for gene therapy in Hunter syndrome
  • Regenxbio GAAP EPS of -$1.41 beats by $0.07, revenue of $28.91M beats by $3.12M
  • Regenxbio Q3 2023 Earnings Preview
  • Stifel starts Regenxbio at buy; cites broad platform, deep portfolio
  • Regenxbio up after hours on early-stage Duchenne candidate
  • Regenxbio GAAP EPS of -$1.66 misses by $0.43, revenue of $19.97M misses by $14.53M
  • Regenxbio Q2 2023 Earnings Preview
  • Catalyst Watch: CPI, major bank earnings, Amazon Prime Day and CAVA ratings
  • Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy
  • Regenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine status
  • Regenxbio GAAP EPS of -$1.53 misses by $0.14, revenue of $19.14M misses by $12.15M
  • Regenxbio Q1 2023 Earnings Preview
  • Regenxbio stock pops on FDA fast track tag for Duchenne gene therapy RGX-202
  • FDA to back accelerated approval pathway for gene therapies
  • Regenxbio GAAP EPS of -$1.38 beats by $0.05, revenue of $31.35M misses by $6.1M
  • Regenxbio Q4 2022 Earnings Preview
  • Regenxbio touts interim results from trial of pediatric rare disease gene therapy
  • Stocks 'disconnected from reality'; Morgan Stanley screens those 'unfairly punished'
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
November 2, 2021 -1.37 / -1.03 30.77M / 25.19M Beat!
August 9, 2021 -1.36 / -1.12 22.04M / 21.17M Beat!
May 5, 2021 -1.2 / -1.28 18.88M / 18.59M Beat!
March 1, 2021 -1.24 / -1.11 21.45M / 26.31M
November 4, 2020 0.23 / -0.9971 98.91M / 21.45M Beat!
August 6, 2020 -0.91 / -0.89 16.57M / 20.46M
May 7, 2020 -1.08 / -0.84 17.64M / 19.62M
February 26, 2020 -0.72 / -0.67 11.77M / 39.67M
November 5, 2019 -0.94 / -0.71 14.7M / 7.46M Beat!
August 7, 2019 -0.04 / -0.58 7.88M / 22.62M
May 7, 2019 -0.89 / -0.86 884K / 8.48M Beat!
February 27, 2019 0.11 / -0.34 40.78M / 17.33M Beat!
November 7, 2018 -0.56 / -0.44 5.31M / 40M
August 8, 2018 0.3 / 0.56 40.03M / 2.08M Beat!
May 8, 2018 3.04 / 1.6 132.39M / 80.5M Beat!
March 6, 2018 -0.51 / -0.82 2.04M / 809.8K
November 8, 2017 -0.67 / -0.72 1.34M / 1.01M Beat!
August 8, 2017 -0.47 / -0.75 6.56M / 1.07M Beat!
May 9, 2017 -0.82 / -0.76 455.0K / 1.42M Beat!
March 7, 2017 -0.74 / -0.77 1.70M / 3.03M
November 9, 2016 -0.69 / -0.75 125.0K / 1.31M Beat!
Date Price Open High Low Vol Change ER
Mar 1 26.45 26.30
27.03
26.08
730.52K 0.92%
Feb 28 26.21 25.67
26.68
25.15
235.53K 1.47%
Feb 25 25.83 25.58
25.95
24.94
645.93K 0.54%
Feb 24 25.69 24.09
25.77
24.09
671.05K 3.34%
Feb 23 24.86 25.46
25.75
24.84
333.22K -1.58%
 
Feb 22 25.26 24.47
25.93
24.11
465.79K 2.60%
Feb 18 24.62 25.45
26.09
24.45
337.24K -4.39%
Feb 17 25.75 26.03
26.26
25.61
306.49K -3.12%
Feb 16 26.58 26.38
27.00
25.96
187.25K -1.37%
Feb 15 26.95 25.44
27.07
25.41
314.40K 7.37%
Feb 14 25.10 25.33
25.55
24.64
393.26K 0%
Feb 11 25.10 25.83
26.39
24.85
411.93K -2.37%
Feb 10 25.71 26.68
27.22
25.02
898.53K -6.98%
Feb 9 27.64 27.47
27.86
26.97
853.10K 1.54%
Feb 8 27.22 27.03
27.42
26.32
339.22K 1.45%
Feb 7 26.83 26.42
27.35
26.06
719.78K 2.80%
Feb 4 26.10 25.02
26.32
24.25
530.47K 5.37%
Feb 3 24.77 25.25
25.71
24.45
352.65K -0.44%
Feb 2 24.88 26.62
27.24
24.69
366.72K -7.27%